Complement Activation and Thrombotic Microangiopathies.
Atypical hemolytic uremic syndrome is a form of thrombotic microangiopathy caused by dysregulation of the alternative complement pathway. There is evidence showing complement activation in other thrombotic microangiopathies. The aim of this study was to evaluate complement activation in different th...
| Autores: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2019 |
| País: | España |
| Institución: | Fundació Sant Joan de Déu |
| Repositorio: | r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu |
| OAI Identifier: | oai:fsjd.fundanetsuite.com:p16827 |
| Acceso en línea: | https://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=16827 |
| Access Level: | acceso abierto |
| Palabra clave: | HELLP syndrome, alternative, antibodies, atypical hemolytic uremic syndrome, complement C9, complement activation, complement membrane, complement pathway, complement system proteins, eculizumab, endothelial cells, female, fibrin, fluorescent antibody technique, humanized, humans, hypertension, malignant, monoclonal, pre-eclampsia, pregnancy, recurrence, thrombotic microangiopathies |
| Sumario: | Atypical hemolytic uremic syndrome is a form of thrombotic microangiopathy caused by dysregulation of the alternative complement pathway. There is evidence showing complement activation in other thrombotic microangiopathies. The aim of this study was to evaluate complement activation in different thrombotic microangiopathies and to monitor treatment response. |
|---|